Behold the Dangers of a One-Trick Pony: Affymax, Inc. (AFFY) and More

This is the danger of investing in a one-trick pony. There are plenty of one-drug biotechs in existence that have fared quite well — including Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) with Soliris – but Affymax is quick to remind us of the dangers of putting all your eggs in just one basket. Only time will tell if Omontys can be saved, but, for the time being, Affymax shares should be counted as damaged goods.

The article Behold the Dangers of a One-Trick Pony originally appeared on Fool.com and is written by Sean Williams.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.